| Reviewed By |
| |
Donald Farquhar
, MD, FRCPC
|
| |
David R. Dixon
, MD, MCISc (FM), CCFP
|
| |
National Education Committee, The University of Western Ontario
|
| |
| Reviewed By |
| |
Jennifer Blake
, MD, MSc, FRCSC
|
| |
Edith Guilbert
, MD, MSc
|
| |
Peter Lin
, MD, CCFP
|
| |
Carl Fournier
, MD, CCFP
|
| |
Bruce H. Wheeler
, MD, CCFP
|
| |
Lydia Hatcher
, MD, CCMF, FCFP
|
| |
Kevin Saunders
, MD, CCFP
|
| |
| Prepared By |
| |
Shelly McNeil
|
| |
Blair W. Seifert
|
| |
Alexandra Henteleff
|
| Reviewed By |
| |
Sol Stern
, MD, BSc, M.Sc
|
| |
Lydia Hatcher
, MD, CCMF, FCFP
|
| |
Bruce H. Wheeler
, MD, CCFP
|
| |
Carl Fournier
, MD, CCFP
|
| |
Phyllis Bedder
, MD
|
| |
Tom Smiley
, BSc.Phm., Pharm.D
|
| |
Michael Boivin
, B.Sc.Phm.
|
| |
| Prepared By |
| |
Lawrence A. Leiter
, MD, FRCPC, FACP
|
| Reviewed By |
| |
Rémi Rabasa-Lhoret
|
| |
Sol Stern
, MD, BSc, M.Sc
|
| |
Lydia Hatcher
, MD, CCMF, FCFP
|
| |
Phyllis Bedder
, MD
|
| |
Bruce H. Wheeler
, MD, CCFP
|
| |
Carl Fournier
, MD, CCFP
|
| |
| Reviewed By |
| |
Jacques Genest
, MD, FRCPC
|
| |
Gregory Searles
, MD, FRCPC
|
| |
Todd Anderson
, MD, FRCPC
|
| |
| Prepared By |
| |
Jane Cole Finlay
, MD, FRCPC
|
| Reviewed By |
| |
Marina Salvadori
|
| |
Vivien Brown
, MDCM, CCFP, FCFP
|
| |
Lydia Hatcher
, MD, CCMF, FCFP
|
| |
Bruce H. Wheeler
, MD, CCFP
|
| |
Carl Fournier
, MD, CCFP
|
| |
Phyllis Bedder
, MD
|
| |
| Prepared By |
| |
Mary-Ann Fitzcharles
, MD, FRCPC, MRCP, M.B.Ch.B
|
| Reviewed By |
| |
Alan Kaplan
, MD
|
| |
Andre Belanger
, MD
|
| |
Ruth Dubin
, MD, PhD, FCFP
|
| |
Lydia Hatcher
, MD, CCMF, FCFP
|
| |
Murray Opdahl
, MD BSPE CCFP
|
| |
Rob Hauptman
, MD
|
| |
| Reviewed By |
| |
Jack Barkin
, MD, FACS, FICS, McertHM, DABU, FRCS
|
| |
Sol Stern
, MD, BSc, M.Sc
|
| |
Pravinsagar Mehta
, MD, CFPC
|
| |
Donald Fay
, MD, CFPC
|
| |
Carl Fournier
, MD, CCFP
|
| |
Martin Gerrettson
, MD, MCFP
|
| |
|
Asthma Virtual PracticeLearning Objectives:- Understand the impact of asthma and the results of poor asthma control on a patient’s quality of life
- Discuss established and new approaches to managing your asthma patients, including the risks and benefits of various treatment approaches
- Understand the role and importance of asthma education and an up-to-date asthma action plan in a patient’s asthma control
- Apply the concepts learned to better counsel patients on their asthma and achieving better control of their disease
A Practical Guide to the H1N1 Vaccine(En Francais)- Using the Canadian and Provincial H1N1 vaccine priority lists, identify patients or patient groups in your practice that would most benefit from early/timely/prompt vaccination.
- For the Canadian vaccine, identify the appropriate dose, administration schedule, and monitoring parameters for infants and young children, children, adolescents, adults and the elderly.
- Understand the risks and benefits of H1N1 vaccination, interactions with other vaccines, and adverse effects management and reporting.
- Review techniques to effectively communicate about immunization.
- Appreciate best practices in immunization, including immunization technique, record keeping and vaccine storage and handling.
Combination Therapy for Type 2 Diabetes(En Francais)Learning Objectives- Explain the mechanisms of action and expected glycemic reductions associated with the various oral antihyperglycemic agents
- Be familiar with the safety and tolerability profiles of the oral antihyperglycemic agents
- Know when to initiate combination therapy in order to improve glycemic control for type 2 diabetes and how to select appropriate agents
- Monitor the efficacy of antihyperglycemic regimens
- Know when to initiate insulin in type 2 diabetes, including how to adjust oral antihyperglycemic therapy in combination with insulin
The 2009 CCS Dyslipidemia GuidelinesAt the conclusion of this program, participants should be able to:- Identify appropriate patients for screening of the lipid profile;
- Stratify patients into low-, moderate- and high-risk groups using the Framingham Risk Score for CVD;
- Identify patients for whom a measurement of hsCRP provides additional important information in CV risk assessment;
- Use apolipoprotein B as an alternate to LDL-C as the primary target for lipid lowering; and
- Identify the goals of lipid-lowering treatment for low-, moderate- and high-risk patients.
Invasive Meningococcal DiseaseLearning Objectives- Examine the epidemiology of invasive meningococcal disease (IMD) in Canada, including changing epidemiological trends
- Review the etiology, transmission, clinical features and complications of meningococcal sepsis and meningitis
- Discuss the evidence-based management of meningococcal meningitis
- Identify approaches to the prevention of IMD, including vaccination of various age groups, prevention in travellers, and compare the different meningococcal vaccines currently available.
- Discuss upcoming advances in the prevention of IMD caused by N. meningitidis type B
- Review the Canadian National Advisory Committee on Immunization (NACI) update (2009) on meningococcal disease and vaccination
Practical Management of Fibromyalgia Patients- Discuss the demographics of fibromyalgia in Canada and possible triggers for this condition.
- Educate patients on the pathophysiology of fibromyalgia.
- Recognize the cluster of symptoms that commonly affect patients with fibromyalgia:
- Pain
- Sleep
- Mood
- Fatigue
- Diagnose a patient with fibromyalgia based on clinical evaluation.
- Individualize and customize a patient’s treatment plan based on the presenting clinical symptoms.
- Educate patients on the efficacy and importance of non-pharmacological and pharmacological treatment options for fibromyalgia.
Refining Risk: Updates in Prostate Cancer Prevention and Screening(En Francais)Learning Objectives- Interpret digital rectal exams (DRE) and PSA testing, including determining prostate volume, for prostate cancer screening.
- Describe the benefits and risks of 5-alpha reductase inhibitors for prostate cancer prevention.
- Counsel patients on prostate cancer screening and preventive measures.
- Select patients appropriate for referral to an urologist for additional evaluation and consideration for prostate cancer prevention with 5-alpha reductase inhibitors.
|
